Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache

NCT00399243 | Unknown Phase 4

• 1 other identifier: DHC08
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This study's hypothesis is the 4mg StatDose sumatriptan is effective for the acute treatment of cluster headache and provides good safety and tolerability across multiple doses of the study medication as well as across multiple attacks of cluster headache. This study seeks to determine the safety and efficacy of the commercially available 4mg StatDose formulation of sumatriptan as an acute treatment of cluster headache. Patients are allowed to use repeated dose of the study medication for a given headache if they have had a partial response to the first dose. They may treat up to 3 attacks of cluster headache with the study medication. Safety assessment will be through adverse event reporting and physical examination. Patients with both episodic cluster headache as well as chronic cluster headache will be studied. Patients must either not have started preventive treatment for cluster headache or be on a stable dose of preventive medication.

Conditions

Episodic Cluster Headache; Chronic Cluster Headache

Keywords

cluster headache; sumatriptan

Outcome Measures

Primary Outcomes (1)

• The primary efficacy parameters will be the percentage of cluster headache attacks that result in the cluster headache pain being reduced to mild or none following a single dose of 4 mg subcutaneous sumatriptan at 15 minutes and at 30 minutes.

  15 minutes and 30 minutes

Secondary Outcomes (12)

• The time meaningful relief of cluster headache.

  Meaningful Relief

• The percentage of attacks that produce a pain free response to a single dose of sumatriptan 4 mg subcutaneous at 15 minutes, 30 minutes and at 1 hour.

  30 minutes and 1 Hour

• The percentage of attacks of migraine that result in resolution of all associated symptoms of cluster headache present at the time of treatment with the study medication as well as achieving a pain free response within 1hour.

  1 hour

• The number of patients reporting adverse effects to study medication, the type of adverse event reported and the percentage of attacks that are associate with the adverse effect.

  Length of study

• The percentage of patients who achieve pain reduced to mild or none at 15 minutes or at 30 minutes respectively for all three treated headache attacks.

  15 minutes and 30 minutes

Interventions

Sumatriptan 4mg Statdose injection DRUG

4mg Sumatriptan Statdose injection for use as acute therapy in a cluster headache. Consistency of response in three attacks will be measured

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is between 18 years and 65 years of age.
• Subject is male or female. If female the subject is:
• non-childbearing potential or,
• child-bearing potential, has a negative pregnancy test at screen, and agrees to one of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the study drug, throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the investigational drug (a minimum of 10 hours); or,
• Female sterilization; or,
• Sterilization of male partner; or,
• Implants of levonorgestrel; or,
• Injectable progestogen; or,
• Oral contraceptive (combined or progestin only) or,
• Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year; or,
• Double barrier method; (2 physical barriers or 1 physical barrier plus spermicide).
• Subject has a diagnosis of cluster headache (IHS).
• Subject has at least 1 previous cycle of cluster headache if episodic or has been in chronic cluster headache for at least 6 months.
• Subject taking any medication for chronic cluster headache prevention has been on a stable regimen for at least 1 month prior to screening.
• Subjects with episodic cluster headache have a history of continuing to have cluster headaches at least once every other day during the first three weeks of treatment with preventive medications.

You may not qualify if:

• Subject has confirmed or suspected ischemic heart disease, Prinzmetal's angina, or signs/symptoms consistent with any of the above.
• Subject has cardiac arrhythmias requiring medication or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion contraindicates participation in this study.
• Subject has a history of congenital heart disease.
• Subject has a history of cerebrovascular pathology including stroke.
• The subject, in the investigator's opinion, is likely to have unrecognized cardiovascular disease.
• Subject has evidence or history of ischemic abdominal syndromes or peripheral vascular disease.
• Subject has uncontrolled hypertension at screening.
• Subject has a history of epilepsy or structural brain lesions which lowers the convulsive threshold.
• Subject has a history of impaired hepatic or renal function.
• Subject is currently taking a monoamine oxidase inhibitor (MAO) or has taken a MAOI within the 2 weeks prior to screen
• Subject is currently taking an ergotamine-containing or ergot-type cluster headache preventive medication like ergotamine tartrate or methylergonovine.
• Subject has hypersensitivity or contraindication to the use of sumatriptan, any of its components, or any other 5-HT1B1D receptor agonist.
• Subject is pregnant, actively trying to become pregnant or breast-feeding
• Subject is of childbearing potential and not using adequate contraceptive measures.
• Subject has evidence of alcohol or substance abuse within the last year which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results.

Sponsors & Collaborators

• Diamond Headache Clinic: lead
• GlaxoSmithKline: collaborator

Study Sites (1)

Diamond Headache Clinic

Chicago, Illinois, 60614, United States

RECRUITING

MeSH Terms

Conditions

Cluster Headache

Interventions

Sumatriptan

Condition Hierarchy (Ancestors)

Trigeminal Autonomic Cephalalgias; Headache Disorders, Primary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Sulfonamides; Amides; Organic Chemicals; Sulfones; Sulfur Compounds; Tryptamines; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Seymour Diamond, MD

  Diamond Headache Clinic

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Fred G Freitag, DO

CONTACT

773 388 6390; research@diamondheadache.com

George Nissan, DO

CONTACT

773 388 6390; research@diamondheadache.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 12, 2006
• First Posted: November 14, 2006
• Study Start: November 1, 2006
• Primary Completion: August 1, 2010
• Study Completion: August 1, 2010
• Last Updated: February 2, 2009

Record last verified: 2009-01

Locations

US (1)